$2.54
0.145.63%
Last update: Oct 27, 11:26 AM
Editas Medicine Inc (EDIT) Stock Price, Quote, News & History
EDITNASDAQ
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.
You can purchase shares of Editas Medicine (NASDAQ:EDIT) through any online brokerage.
Other companies in Editas Medicine’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Editas Medicine has a consensus price target of $6.76.
The stock price for Editas Medicine (NASDAQ: EDIT) is $2.535 last updated October 27, 2026 at 11:26 AM EDT.
There are no upcoming dividends for Editas Medicine.
Editas Medicine does not have any upcoming earnings scheduled.
There is no upcoming split for Editas Medicine.
Editas Medicine is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform...
